GLP1R and metabolic dysfunction-associated steatotic liver disease: Patients on GLP-1 receptor agonists (e.g., liraglutide, semaglutide) had a lower prevalence of NAFLD (25% in the NAFLD group vs. 30.6% in the non-NAFLD group) (p = 0.018).